LILRB1 抗体 (AA 483-650)
Quick Overview for LILRB1 抗体 (AA 483-650) (ABIN7158264)
抗原
See all LILRB1 抗体适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            抗原表位
- AA 483-650
- 
                                            交叉反应
- 人, 大鼠
- 
                                            纯化方法
- >95%, Protein G purified
- 
                                            免疫原
- Recombinant Human Leukocyte immunoglobulin-like receptor subfamily B member 1 protein (483-650AA)
- 
                                            亚型
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- Recommended dilution: WB:1:500-1:5000, IHC:1:200-1:500, IF:1:50-1:200,
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            缓冲液
- 
                        Preservative: 0.03 % Proclin 300
 Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4
- 
                                            储存液
- ProClin
- 
                                            注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            储存条件
- -20 °C,-80 °C
- 
                                            储存方法
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
 
- 
                                            
- 
    - LILRB1 (Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM and ITIM Domains), Member 1 (LILRB1))
- 
                                            别名
- LILRB1
- 
                                            背景
- 
                        Background: Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. Aliases: CD85 antibody, CD85 antigen antibody, CD85 antigen like family member J antibody, CD85 antigen-like family member J antibody, CD85j antibody, CD85j antigen antibody, Ig like transcript 2 antibody, ILT 2 antibody, ILT-2 antibody, ILT2 antibody, immunoglobulin like transcript 2 antibody, Immunoglobulin-like transcript 2 antibody, leukocyte Ig like receptor 1 antibody, Leukocyte immunoglobulin like receptor 1 antibody, leukocyte immunoglobulin like receptor subfamily B member 1 antibody, Leukocyte immunoglobulin like receptor subfamily B member 1 precursor antibody, leukocyte immunoglobulin like receptor subfamily B member 1 soluble isoform antibody, leukocyte immunoglobulin like receptor, subfamily B, member 1 antibody, Leukocyte immunoglobulin-like receptor 1 antibody, Leukocyte immunoglobulin-like receptor subfamily B member 1 antibody, leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform antibody, leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 antibody, LILRB1 antibody, LIR 1 antibody, LIR-1 antibody, LIR1 antibody, LIRB1_HUMAN antibody, MIR 7 antibody, MIR-7 antibody, MIR7 antibody, Monocyte/macrophage immunoglobulin like receptor 7 antibody, Monocyte/macrophage immunoglobulin-like receptor 7 antibody, PIR B antibody, PIRB antibody 
- 
                                            UniProt
- Q8NHL6
- 
                                            途径
- Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response
 抗原
- 
                    
 
                                     
                                     
                                    